$AMPH News
Last published 13h ago
- 13h agoAMPHAmphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in LondonPR NewswireAmphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration,...
- 6d agoAMPHThird Quarter Earnings Call - AMPHASTAR PHARMACEUTICALS INCEarnings Call TranscriptsGreetings and welcome to the Amphistar Pharmaceuticals, Inc. Third Quarter Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow a formal presentation. If anyo
- 6d agoAMPHAmphastar Pharmaceuticals, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 6d agoAMPHThird Quarter Earnings Call - AMPHASTAR PHARMACEUTICALS INCEarnings Call TranscriptsGreetings and welcome to the Amphistar Pharmaceuticals, Inc. Third Quarter Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow a formal presentation. If anyo
- 6d agoAMPHThird Quarter Earnings Call - AMPHASTAR PHARMACEUTICALS INCEarnings Call TranscriptsGreetings and welcome to the Amphistar Pharmaceuticals, Inc. Third Quarter Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow a formal presentation. If anyo
- 1w agoAMPHAmphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 5, 2026PR NewswireRANCHO CUCAMONGA, Calif., October 29, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that the Company will release results for its third quarter of 2026 ended September 30, 2026,
- 2mo agoAMPHWELLS FARGO 21ST ANNUAL HEALTHCARE CONFERENCE - AMPHASTAR PHARMACEUTICALS INCEarnings Call TranscriptsAll right, we'll get started with our next one. I'm Ben Burnett, biotech analyst at Wells Fargo. Pleased to be here with the Amphistar management team. We have Bill Peters, CFO, and Tony Morris, regulatory. Thank you all
- 2mo agoAMPHAmphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare ConferencePR NewswireAmphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical...
- 3mo agoAMPHAmphastar Pharmaceuticals, Inc. - Second Quarter Earnings Call - AMPHASTAR PHARMACEUTICALS INCEarnings Call TranscriptsGreetings and welcome to the Amphistar Pharmaceuticals, Inc. Second Quarter Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow a formal presentation. If any
- 3mo agoAMPHSecond Quarter Earnings Call - AMPHASTAR PHARMACEUTICALS INCEarnings Call TranscriptsGreetings and welcome to the Amphistar Pharmaceuticals, Inc. Second Quarter Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow a formal presentation. If any
- 3mo agoAMPHAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026PR NewswireAmphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) ("Amphastar" or the "Company"), a biopharmaceutical company focused on developing, manufacturing, and...
- 3mo agoAMPHAmphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6, 2026PR NewswireAmphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that the Company will release results for its second quarter of 2026 ended June 30,...
- 3mo agoSDZ-CHHIK-GBHIK-AEFME-DE+5Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supplyCNBCTrump's generic drug tariff plan raises questions over prices, U.S. manufacturing and which drugmakers stand to gain or lose as details remain unclear.
- 4mo agoAMPHFDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid OverdoseFDA Press ReleasesThe U.S. Food and Drug Administration (FDA) today approved another over-the-counter (OTC) intranasal naloxone product, Rextovy, a 4 milligram (mg) naloxone hydrochloride nasal spray for the emergency treatment of opioid overdose. Consumers may directly purchase this product without a prescription in places such as pharmacies, convenience stores, and online. This action aligns with President Trump’ ...
- 5mo agoAMPHAmphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare ConferenceACCESS NewswireRANCHO CUCAMONGA, CA / ACCESS Newswire / May 27, 2026 / Amphastar Pharmaceuticals, Inc. announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will be presenting at
- 6mo agoAMPH2026 GLOBAL HEALTHCARE CONFERENCEAMPHASTAR PHARMACEUTICALS INCEarnings Call TranscriptsAll right, everybody. We're going to get going here with our next company presenter at the B of A Annual Healthcare Conference. My name is Jason Gerberry. I cover pharma and biotech at B of A, and I'm pleased to be intro
- 6mo agoAMPHFirst Quarter Earnings Call - AMPHASTAR PHARMACEUTICALS INCEarnings Call TranscriptsGreetings and welcome to the Amphisar Pharmaceuticals first quarter earnings call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone sh
- 6mo agoAMPHAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026ACCESS NewswireNet revenues of $171.2 million for the three months ended March 31, 2026GAAP net income of $6.4 million, or $0.14 per share, for the first quarterAdjusted non-GAAP net income of $19.5 million, or $0.42 per share, for the
- 6mo agoAMPHAmphastar Pharmaceuticals to Present at the 2026 Bank of America Health Care ConferenceACCESS NewswireRANCHO CUCAMONGA, CA / ACCESS Newswire / May 6, 2026 / Amphastar Pharmaceuticals, Inc. announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be
- 6mo agoAMPHAmphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7, 2026ACCESS NewswireRANCHO CUCAMONGA, CA / ACCESS Newswire / April 30, 2026 / Amphastar Pharmaceuticals, Inc. announced today that the Company will release results for its first quarter of 2026, ended March 31, 2026, after the
- 7mo agoAMPHAmphastar Pharmaceuticals to Present at the 25th Annual Needham Healthcare ConferenceACCESS NewswireRANCHO CUCAMONGA, CA / ACCESS Newswire / April 6, 2026 / Amphastar Pharmaceuticals, Inc. announced today that Bill Peters, CFO, Tony Marrs, EVP of Regulatory Affairs and
- 8mo agoAMPHAmphastar Pharmaceuticals, Inc. - Fourth Quarter Earnings Call - AMPHASTAR PHARMACEUTICALS INCEarnings Call TranscriptsGreetings and welcome to the AMPA star pharmaceuticals fourth quarter earnings call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. If anyone
- 8mo agoAMPHAmphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2025ACCESS NewswireNet revenues of $183.1 million and $719.9 million, respectively, for the three months and fiscal year ended December 31, 2025GAAP net income of $24.4 million, or $0.51 per share and $98.1 million, or $2.03 per share,
- 8mo agoAMPHAmphastar Announces FDA Approval for Ipratropium Bromide HFAACCESS NewswireRANCHO CUCAMONGA, CA / ACCESS Newswire / February 24, 2026 / Amphastar Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved the Company's Abbreviated New Drug
- 8mo agoAMPHAmphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 26, 2026ACCESS NewswireRANCHO CUCAMONGA, CA / ACCESS Newswire / February 20, 2026 / Amphastar Pharmaceuticals, Inc. announced that the Company will release results for its fourth quarter of 2025 ended December 31, 2025, after the
- 11mo agoAMPHAmphastar Announces FDA Approval for Teriparatide InjectionACCESS NewswireRANCHO CUCAMONGA, CA / ACCESS Newswire / December 15, 2025 / Amphastar Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved the Company's Abbreviated New Drug
- 11mo agoAMPHAmphastar Pharmaceuticals to Present at the 37th Annual Piper Sandler Healthcare ConferenceACCESS NewswireRANCHO CUCAMONGA, CA / ACCESS Newswire / November 24, 2025 / Amphastar Pharmaceuticals, Inc. announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be
- 12mo agoAMPHAmphastar Pharmaceuticals to Present at the Jefferies Global Healthcare ConferenceACCESS NewswireRANCHO CUCAMONGA, CA / ACCESS Newswire / November 12, 2025 / Amphastar Pharmaceuticals, Inc. announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will be
- 1y agoAMPHAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2025ACCESS NewswireReports Net Revenues of $191.8 million for the Three Months Ended September 30, 2025GAAP net income of $17.4 million, or $0.37 per share, for the third quarterAdjusted non-GAAP net income of $44.7 million, or $0.93 per
- 1y agoAMPHAmphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6th, 2025ACCESS NewswireRANCHO CUCAMONGA, CA / ACCESS Newswire / October 27, 2025 / Amphastar Pharmaceuticals, Inc. announced that the Company will release results for its third quarter of 2025 ended September 30, 2025, after the
- 1y agoAMPHAmphastar Pharmaceuticals to Present at the 2025 Wells Fargo Healthcare ConferenceACCESS NewswireRANCHO CUCAMONGA, CA / ACCESS Newswire / August 28, 2025 / Amphastar Pharmaceuticals, Inc. announced today that Bill Peters, CFO and Dan Dischner, SVP of Corp. Communication, will be participating in an
- 1y agoAMPHAmphastar Pharmaceuticals Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology Co., Ltd.ACCESS NewswireAgreement strengthens proprietary peptide pipeline targeting high-value oncology and ophthalmology indications RANCHO CUCAMONGA, CA / ACCESS Newswire / August 12, 2025 / Amphastar Pharmaceuticals, Inc.
- 1y agoAMPHAmphastar Announces FDA Approval for Iron Sucrose Injection, USPACCESS NewswireAccording to the FDA, Amphastar's iron sucrose injection meets the criteria for bioequivalence and therapeutic equivalence to Venofer® for the treatment of iron deficiency anemia in patients with chronic kidney
- 1y agoAMPHAmphastar Pharmaceuticals, Inc. (AMPH) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoAMPHAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2025ACCESS Newswire- Reports Net Revenues of $174.4 million for the Three Months Ended June 30, 2025- GAAP net income of $31.0 million, or $0.64 per share, for the second quarter- Adjusted non-GAAP net income of $40.9 million, or $0.85 per
- 1y agoAMPHAmphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 7th, 2025ACCESS NewswireRANCHO CUCAMONGA, CA / ACCESS Newswire / July 29, 2025 / Amphastar Pharmaceuticals, Inc. announced that the Company will release results for its second quarter of 2025 ended June 30, 2025, after the market
- 1y agoAMPHAmphastar Pharmaceuticals Aims to Quadruple Domestic Manufacturing Capacity at Rancho Cucamonga HeadquartersACCESS NewswireRANCHO CUCAMONGA, CA / ACCESS Newswire / July 14, 2025 / Amphastar Pharmaceuticals, Inc. , a bio-pharmaceutical company focused on developing, manufacturing, and marketing complex generic and proprietary
- 1y agoAMPHAmphastar Pharmaceuticals to Present at the Jefferies Global Healthcare ConferenceACCESS NewswireRANCHO CUCAMONGA, CA / ACCESS Newswire / May 22, 2025 / Amphastar Pharmaceuticals, Inc. announced today that Bill Peters, CFO and Jacob Liawatidewi, EVP of Corporate Administration, will be participating in
- 1y agoAMPHAmphastar Pharmaceuticals to Present at the 2025 Bank of America Health Care ConferenceACCESS NewswireRANCHO CUCAMONGA, CA / ACCESS Newswire / May 9, 2025 / Amphastar Pharmaceuticals, Inc. announced today that Bill Peters, CFO and Dan Dischner, SVP of Corp. Communication, will be participating in an
- 1y agoAMPHAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025ACCESS NewswireReports Net Revenues of $170.5 Million for the Three Months Ended March 31, 2025 RANCHO CUCAMONGA, CA / ACCESS Newswire / May 7, 2025 / Amphastar Pharmaceuticals, Inc. ("Amphastar" or the
- 1y agoAMPHAmphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2025ACCESS NewswireRANCHO CUCAMONGA, CA / ACCESS Newswire / April 30, 2025 / Amphastar Pharmaceuticals, Inc. announced that the Company will release results for its first quarter of 2025 ended March 31, 2025, after the market
- 1y agoAMPHAmphastar Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare ConferenceACCESS NewswireRANCHO CUCAMONGA, CA / ACCESS Newswire / April 3, 2025 / Amphastar Pharmaceuticals, Inc. announced today that Bill Peters, CFO and Dan Dischner, SVP of Corp. Communication, will be participating in an
- 1y agoAMPHInternational Medication Systems, Ltd. Receives FDA's Drug Shortage Assistance AwardACCESS NewswireRecognized for contributions to address shortage of epinephrine injection, 0.1 mg/mL syringes RANCHO CUCAMONGA, CA / ACCESS Newswire / March 28, 2025 / Amphastar Pharmaceuticals, Inc. today announced that
- 1y agoAMPHAegis Therapeutics, LLC et al. vs Amphastar Pharmaceuticals, Inc. - AIA Trial, DismissedUS Patent Trial and Appeal Board
- 1y agoAMPHAmphastar Pharmaceuticals to Present at the Barclays 27th Annual Global Healthcare ConferenceACCESS NewswireRANCHO CUCAMONGA, CA / ACCESS Newswire / March 5, 2025 / Amphastar Pharmaceuticals, Inc. announced today that Bill Peters, CFO and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations will be
- 1y agoAMPHAmphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2024ACCESS NewswireReports Net Revenues of $186.5 Million for the Three Months Ended December 31, 2024 RANCHO CUCAMONGA, CA / ACCESS Newswire / February 27, 2025 / Amphastar Pharmaceuticals, Inc. ("Amphastar" or the
- 1y agoAMPHAmphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 27, 2025ACCESS NewswireRANCHO CUCAMONGA, CA / ACCESS Newswire / February 20, 2025 / Amphastar Pharmaceuticals, Inc. announced that the Company will release results for its Fourth quarter of 2024 ended December 31, 2024, after the
- 1y agoAMPHAmphastar Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceACCESS NewswireRANCHO CUCAMONGA, CA / ACCESSWIRE / January 8, 2025 / Amphastar Pharmaceuticals, Inc. announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the 43rd Annual J.P.
- 1y agoAMPHAmphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare ConferenceACCESS NewswireRANCHO CUCAMONGA, CA / ACCESSWIRE / November 26, 2024 / Amphastar Pharmaceuticals, Inc. announced today that Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, will participate in an
- 1y agoAMPHAmphastar Pharmaceuticals to Present at the Jefferies London Healthcare ConferenceACCESS NewswireRANCHO CUCAMONGA, CA / ACCESSWIRE / November 13, 2024 / Amphastar Pharmaceuticals, Inc. announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will participate in an